Amyloid fibril polymorphism: a challenge for molecular imaging and therapy

Area of Science:

• Neuroscience
• Molecular Biology
• Pathology

Background:

• Misfolded proteins (MPs) accumulate in various chronic degenerative diseases, either systemically or localized to specific cell types.
• In neurodegenerative diseases (NDs), MP accumulation progressively spreads throughout the nervous system.
• Current treatments for NDs are palliative, not curative, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To explore the hypothesis that misfolded proteins (MPs) are active carriers of pathogenicity, not just markers.
• To discuss comprehensive molecular approaches for understanding MP conformational variations (polymorphism).
• To examine the implications of MP polymorphism on spreading, toxicity, and targeting for imaging and therapy.

Main Methods:

• Review of comprehensive molecular studies.
• Analysis of research on misfolded protein conformational variations (polymorphism).
• Examination of studies on MP spreading pathways and toxicity.

Main Results:

• Misfolded proteins (MPs) exhibit conformational variations (polymorphism) that influence their spreading and toxicity.
• MP polymorphism impacts the development and progression of neurodegenerative diseases.
• Targeting MPs offers potential for selective imaging, prognostic diagnosis, and novel therapies.

Conclusions:

• Misfolded proteins (MPs) are active agents in neurodegenerative disease pathogenesis.
• Understanding MP polymorphism is crucial for developing effective treatments.
• Advances in studying MP structure and behavior encourage future research for therapeutic interventions.